Potentiation of Kinin Analogues by Ramiprilat Is Exclusively Related to Their Degradation
- 1 July 2001
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 38 (1) , 142-146
- https://doi.org/10.1161/01.hyp.38.1.142
Abstract
The potentiation of kinin actions represents a cardioprotective property of ACE inhibitors. Although a clear contribution to this effect is related to the inhibition of bradykinin (BK) breakdown, the high efficacy of potentiation and the ability of ACE inhibitors to provoke a B 2 -receptor-mediated response even after receptor desensitization has also triggered hypotheses concerning additional mechanisms of kinin potentiation. The application of kinin analogues with enhanced metabolic stability for the demonstration of degradation-independent mechanisms of potentiation, however, has yielded inconsistent results. Therefore, the relation between the susceptibility of B 2 -agonists to ACE and the potentiation of their actions by ACE inhibitors was investigated with the use of minimally modified kinin derivatives that varied in their degree of ACE resistance. The B 2 -agonists BK, d -Arg-[Hyp 3 ]-BK, [Hyp, 3 Tyr(Me) 8 ]-BK, [ΔPhe 5 ]-BK, [D-NMF 7 ]-BK, and [Phe 8 ψ(CH 2 -NH)Arg 9 ]-BK were tested for degradation by purified rabbit ACE and for their potency in contracting the endothelium-denuded rabbit jugular vein in the absence and presence of ramiprilat. Purified ACE degraded d -Arg-[Hyp 3 ]-BK and [Hyp, 3 Tyr(Me) 8 ]-BK at 81% and 71% of BK degradation activity, respectively, whereas other peptides were highly ([ΔPhe 5 ]-BK) or completely ([D-NMF 7 ]-BK, [Phe 8 ψ(CH 2 -NH)Arg 9 ]-BK) resistant. The EC 50 of BK-induced venoconstriction (1.15±0.2 nmol/L) was reduced by a factor of 5.7 in the presence of ramiprilat. Likewise, d -Arg-[Hyp 3 ]-BK and [Hyp, 3 Tyr(Me) 8 ]-BK were both significantly potentiated by a factor of 4.4, whereas the activities of the other agonists were not affected. Ramiprilat exerted no influence on the maximum contraction induced by any of the agonists. It is concluded that the potentiation of kinin analogues during ACE inhibition correlates quantitatively with the susceptibility of each substance to degradation by ACE. As such, no evidence of degradation-independent potentiating actions of ACE inhibitors could be obtained.Keywords
This publication has 14 references indexed in Scilit:
- Replacement of the Transmembrane Anchor in Angiotensin I-converting Enzyme (ACE) with a Glycosylphosphatidylinositol Tail Affects Activation of the B2 Bradykinin Receptor by ACE InhibitorsJournal of Biological Chemistry, 2000
- Structural requirements for B2-agonists with improved degradation stabilityImmunopharmacology, 1999
- Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive SubjectsNew England Journal of Medicine, 1998
- Intravascular and interstitial degradation of bradykinin in isolated perfused rat heartBritish Journal of Pharmacology, 1997
- ACE inhibitor potentiation of bradykinin‐induced venoconstrictionBritish Journal of Pharmacology, 1997
- Highly Selective Bradykinin Agonists and Antagonists with Replacement of Proline Residues byN-Methyl-d- andl-phenylalanineJournal of Medicinal Chemistry, 1996
- Co-solubilization of bradykinin B2 receptors and angiotensin-converting enzyme from guinea pig lung membranesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1994
- Hemodynamic Effects of Bradykinin on Systemic and Pulmonary Circulation in Healthy and Hypertensive HumansJournal of Cardiovascular Pharmacology, 1990
- [Phe8ψ(CH2-NH)Arg9]bradykinin, a B2 receptor selective agonist which is not broken down by either kininase I or kininase IIEuropean Journal of Pharmacology, 1988
- An Intramolecularly Quenched Fluorescent Tripeptide as a Fluorogenic Substrate of Angiotensin‐I‐Converting Enzyme and of Bacterial Dipeptidyl CarboxypeptidaseEuropean Journal of Biochemistry, 1978